Hybio Pharmaceutical Financial Flexibility Index
Hybio Pharmaceutical financial flexibility index. Hybio Pharmaceutical (300199) has a Financial Flexibility Index of 0.09x as of September 2025. Free cash flow of CN¥213.38 Million (operating CF CN¥117.78 Million minus capex CN¥95.60 Million) represents 0% of total liabilities (CN¥2.50 Billion). Explore 300199 capital expenditure intensity to see what proportion of operating cash flow is directed to capital expenditures.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of Hybio Pharmaceutical (2007–2024)
Financial flexibility index of Hybio Pharmaceutical from 2007 to 2024. Historical Financial Flexibility Index trend for Hybio Pharmaceutical across 18 annual periods. Check 300199 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Hybio Pharmaceutical Financial Flexibility Index by Year (2007–2024)
Hybio Pharmaceutical financial flexibility index by year from 2007 to 2024. Year-by-year free cash flow to debt coverage for Hybio Pharmaceutical. For the full cash flow conversion analysis, see 300199 cash generation efficiency.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.12x | CN¥280.54 Million | CN¥164.71 Million | CN¥2.41 Billion | ▲ +270.9% |
| 2023 | 0.03x | CN¥78.23 Million | CN¥-3.54 Million | CN¥2.49 Billion | ▼ -64.7% |
| 2022 | 0.09x | CN¥205.65 Million | CN¥15.81 Million | CN¥2.31 Billion | ▼ -43.6% |
| 2021 | 0.16x | CN¥355.83 Million | CN¥156.83 Million | CN¥2.26 Billion | ▲ +26.5% |
| 2020 | 0.12x | CN¥291.65 Million | CN¥47.99 Million | CN¥2.34 Billion | ▼ -54.0% |
| 2019 | 0.27x | CN¥674.79 Million | CN¥104.64 Million | CN¥2.49 Billion | ▲ +48.9% |
| 2018 | 0.18x | CN¥412.57 Million | CN¥47.00 Million | CN¥2.27 Billion | ▼ -40.9% |
| 2017 | 0.31x | CN¥434.88 Million | CN¥213.74 Million | CN¥1.41 Billion | ▼ -36.4% |
| 2016 | 0.48x | CN¥412.46 Million | CN¥296.41 Million | CN¥852.42 Million | ▼ -11.7% |
| 2015 | 0.55x | CN¥497.82 Million | CN¥138.84 Million | CN¥908.68 Million | ▼ -7.8% |
| 2014 | 0.59x | CN¥238.59 Million | CN¥153.43 Million | CN¥401.32 Million | ▼ -78.6% |
| 2013 | 2.77x | CN¥456.33 Million | CN¥153.48 Million | CN¥164.48 Million | ▼ -3.4% |
| 2012 | 2.87x | CN¥308.57 Million | CN¥87.19 Million | CN¥107.42 Million | ▲ +13.5% |
| 2011 | 2.53x | CN¥150.74 Million | CN¥72.48 Million | CN¥59.56 Million | ▲ +5.5% |
| 2010 | 2.40x | CN¥77.52 Million | CN¥54.69 Million | CN¥32.30 Million | ▲ +274.1% |
| 2009 | 0.64x | CN¥35.11 Million | CN¥26.11 Million | CN¥54.73 Million | ▼ -77.4% |
| 2008 | 2.84x | CN¥106.02 Million | CN¥45.75 Million | CN¥37.32 Million | ▼ -49.7% |
| 2007 | 5.65x | CN¥53.93 Million | CN¥49.04 Million | CN¥9.54 Million | — |